MedTrace Logo

Personalized Oncogenomics (POG) Program of British Columbia

NCT02155621 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2025-09-22

No results posted yet for this study

Summary

The genomic heterogeneity of cancers implies that to effectively use targeted therapies the investigators will need to assess each individual cancer and match it to a biologically relevant targeted therapy. The investigators will use full genome sequencing to try to identify cancer "drivers" and corresponding drugs that may inhibit these pathways.

Conditions

  • Metastatic Cancers
  • Advanced Cancers
  • Cancers That Cannot be Treated With Curative Intent

Interventions

GENETIC

Genome sequencing

Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis

Sponsors & Collaborators

  • BC Cancer Foundation

    collaborator OTHER

  • British Columbia Cancer Agency

    lead OTHER

Principal Investigators

  • Janessa J Laskin, MD · British Columbia Cancer Agency

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02155621 on ClinicalTrials.gov